GlassScriptPhysician profile
Hannah Edwards
NPI 1235793449
$2,970.81
in general payments reported to CMS, 2019-2025
33 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $121 · 2023: $604 · 2024: $713 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,825 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,824.67 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $455.82 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $335.52 | 2022-2025 | |
| Amgen INC. | $323.10 | 2023-2025 | Otezla, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $261.55 | 2022-2025 | Farxiga, Airsupra |
| Abbvie INC. | $247.24 | 2022-2025 | Vraylar |
| Lilly USA, LLC | $227.81 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.14 | 2024-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.67 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $93.21 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $75.41 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $74.99 | 2024-2025 | Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $48.22 | 2025 | Auvelity |
| Exact Sciences Corporation | $45.68 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $43.85 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $42.76 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.91 | 2024-2025 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $38.22 | 2025 | Gvoke Hypopen |
| Medtronic, INC. | $36.80 | 2024 | Mazor X System |
| Merck Sharp & Dohme LLC | $33.92 | 2023-2025 | Verquvo, Belsomra, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $28.17 | 2022 | |
| Inspire Medical Systems, INC. | $26.59 | 2025 | Inspire |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $23.94 | 2025 | Vpriv |
| Corium, LLC | $23.75 | 2023 | Adlarity |
| Nevro Corp. | $23.08 | 2023 | Senza |
| E.R. Squibb & Sons, L.L.C. | $21.57 | 2024 | Eliquis |
| Kyowa Kirin, INC. | $20.72 | 2025 | |
| Cequr Corporation | $20.31 | 2025 | Cequr Simplicity |
| Seqirus USA INC | $19.15 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Boston Scientific Corporation | $18.19 | 2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $17.84 | 2025 | |
| Dexcom, INC. | $16.63 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $14.05 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.